At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
In 2 recent phase 3 studies presented at the 2024 Annual Meeting of The Menopause Society, patient-reported sleep disturbances and impairments were improved among patients using fezolinetant to reduce vasomotor symptoms (VMS).1
Fezolinetant is a nonhormonal, selective neurokinin 3 receptor antagonist used to reduce VMS caused by menopause. Investigators conducted a post hoc analysis to evaluate sleep disturbances and impairments in women with or without sleep disturbances at baseline.
The SKYLIGHT 1 (NCT04003155) and 2 (NCT04003142) trials included women aged 40 to 65 years with moderate-to-severe VMS caused by menopause. These participants were randomized to receive fezolinetant 30 mg, 45 mg, or placebo.
Treatment lasted for a double-blind period of 12 weeks. At the end of the 12-week period, participants entered a 40-week period where those receiving fezolinetant continued their initial dose while those taking placebo were randomized to receive fezolinetant 30 mg or 45 mg.
Outcome measures included the change in Patient-Reported Outcomes Measurement Information System Sleep Disturbance – Short Form 8b (PROMIS SD SF 8b) scores from baseline to week 12 and PROMIS Sleep-Related Impairment – Short Form 8a (PROMIS SRI SF 8a) scores from baseline to each visit. A PROMIS SD SF 8b of 55 or more at baseline indicated sleep disturbances.
Changes from baseline to weeks 12 and 52 were measured in all assessments. A mixed model repeated measures approach was used to generate 95% confidence intervals.
There were 1022 women included in the analysis, 648 of whom reported sleep disturbances at baseline while 372 did not and 2 had missing sleep disturbance data. Respondents with sleep disturbances at baseline reported more significant improvement during the trial period.
Both doses of fezolinetant led to significantly improved sleep disturbances and impairment at week 12 when compared to placebo among both women with and without sleep disturbance at baseline. The rate of fezolinetant use was also greater than placebo use at week 12, and the reported improvements remained by week 52.
These results indicated significantly improved patient-reported sleep disturbances and impairments among women with and without sleep disturbance at baseline receiving fezolinetant. Investigators concluded findings from the SKYLINE 1 and 2 trials may be applied to a wider population of menopausal women seeking VMS treatment.
This data supports the findings of the phase 3b DAYLIGHT (NCT05033886) clinical trial evaluating the safety and efficacy of fezolinetant against VMS.2 The DAYLIGHT study included 450 women across 69 different sites in Turkey, Canada, and Europe.
The reduction in moderate-to-severe VMS over a 25-week period was compared among patients receiving fezolinetant 45 mg vs placebo. This endpoint was successfully reached in the fezolinetant group, and positive safety data was also reported.
Treatment-emergent adverse events (TEAEs) were reported in under 5% of patients, with common TEAEs including headache and COVID-19. Manufacturers have advised against fezolinetant use among patients with a severe kidney condition or kidney failure, cirrhosis, or taking CYP1A2 inhibitors.
Additional adverse events of fezolinetant include back pain, insomnia, diarrhea, and hot flashes. Potential severe side effects include liver problems which may present through nausea, vomiting, jaundice, and abdomen pain.
References
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 3rd 2021In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Listen
Intravaginal estrogen shows promise for treating postmenopausal vaginal atrophy
September 30th 2024A recent study reveals that localized estrogen treatment significantly improves vaginal atrophy and vaginitis symptoms in postmenopausal women, offering new insights into tailored hormone therapies.
Read More